In this review:
- Dual anticoagulation/antiplatelet for peripheral arterial disease
- 6 weeks vs 3 months of anticoagulation for VTE in children
- Trends in VTE and death with COVID-19
- Estimating bleeding risk in CAT
- Predictors of lupus anticoagulant test variability and thrombotic events
- VWF-A1 domain binding aptamer and factor VIII half-life
- Oral pazopanib for hereditary haemorrhagic telangiectasia
- AstraZeneca vaccineinduced immune thrombotic thrombocytopenia
- Management of subsegmental PE without anticoagulation
- Brain lesion progression in antiphospholipid syndrome
Please login below to download this issue (PDF)